Idenix Pharmaceuticals, Inc. (IDIX)

awolfson1015 (30.35) Submitted: 6/26/07 7:52 AM : Start Price: $6.72 IDIX Score: 18.91

The company is sitting on a good amount of cash and has a major backer in the form of Novartis (NVS -- owns over 50% of IDIX's shares). Idenix currently sells a Hepatitis B drug and has a Hep C drug in Phase II trials. They are also working on an HIV drug that is in the extreme early phases of development. The Hep C drug will be used in combination with other drugs, but experienced a setback last year because of GI problems in some patients.

Honestly, I'm not a big biotech/pharma investor, but I like the idea behind this company's products and the potential for both the current Hep B drug and the possible Hep C drug. I generally avoid this realm because I don't have the background to understand the chemistry behind the drugs, but I figured this was an interesting situation to monitor through CAPS. Right now, the market is valuing this company as if it had very little chance at a future. NVS' support and the Hep B drug currently on market seem to mitigate against this pessimism.

Report this Post Replies: 0 | Reply | Permalink